Marica Eoli

Fondazione IRCCS Istituto Neurologico Carlo Besta — Italy

Medicine · Health Sciences

42h-index12.0kcitations388works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(196), Cancer, Hypoxia, and Metabolism(54), Neurofibromatosis and Schwannoma Cases(50), Brain Metastases and Treatment(35), Neuroblastoma Research and Treatments(30)

Publications382 total

Supplementary Tables S1-S3 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S2 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S8 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S3 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S7 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S1. from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S4 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S5 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
Supplementary Figure S6 from <i>LZTR1</i> Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
2025Open Access
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Journal of Clinical Oncology·2025Open Access
CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA
Neuro-Oncology·2025Open Access
P14.12.B CLINICAL AND MOLECULAR SPECTRUM OF NON NF2 RELATED SCHWANNOMATOSIS
Neuro-Oncology·2025Open Access
RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity
Human Genomics·2025Open Access
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy
Nature Communications·2025Open Access
The anti‐aging Klotho protects glioblastoma macrophages from radiotherapy‐induced inflammation and predicts immunotherapy response
International Journal of Cancer·2025Open Access
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
The Lancet·2025· 13 cited
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
Journal of Clinical Oncology·2025
Medullary thyroid carcinoma and c-cell hyperplasia in patients affected with neurofibromatosis type 1
Endocrine Abstracts·2025
Abstract 6350: Exploring genetic and non-genetic evolution of glioblastoma by integrating single cell DNA and RNA sequencing
Cancer Research·2025
High-grade gliomas with autoimmune encephalitis-like presentation: case report and systematic review of the literature
Neurological Sciences·2025· 2 cited
page 1 of 20Next →

Frequent Co-authors

Gaetano Finocchiaro(18), Andrea Salmaggi(15), Bianca Pollo(13), Giovanni Broggi(13), Elena Anghileri(11), Antonio Silvani(11), A. Boiardi(11), E. Lamperti(7), Giuseppe Lombardi(6), Francesco Acerbi(6), Paolo Ferroli(6), Maria Grazia Bruzzone(6), Lucia Cuppini(6), Valeria Cuccarini(6), Antonio Iavarone(5), Alba A. Brandes(5), Vittorina Zagonel(5), Rosina Paterra(5), Graziella Filippini(5), L. La Mantia(5)